New Delhi: A group of top Indian pharma companies has reached out to the central government opposing a proposal to allow government-run Janaushadhi Kendras to dispense substitutes of prescription medications, …
New Delhi: A total of 24 blockbuster drugs, with global sales worth $251 billion, have lost or are set to lose their patents in the US by 2030, which could …
Marksans, whose product portfolio includes therapeutic segments of cardiovascular, central nervous system, antidiabetic, pain management, gastroenterology and anti-allergy drugs and whose market capitalisation stood at Rs 5,299.75 crore in August last …